Just processed by the SEC on this bright Friday afternoon: TraceLink, a software-as-a-service platform for tracking pharmaceuticals and trying to weed out counterfeit prescription drugs in the process, has raised $60 million in Series D funding. The filing shows that 18 firms participated, including, presumably, Goldman Sachs, whose growth equity arm had led the company’s $51.5 million …